Pharma — Januar 2024
-
ALK overtager amerikanske selskab bag
hudtest https://www.proinvestor.com/investornyt/1099119/alk-overtager-amerikanske-selskab-bag-hudtest -
Lundbeck-topchef ser gode muligheder for at bygge bro over patentudløb https://www.proinvestor.com/investornyt/1100878/lundbeck-topchef-ser-gode-muligheder-for-at-bygge-bro-over-patentudlob
-
7 Incredible Reasons to Buy Pfizer Stock Right Now https://www.proinvestor.com/investornyt/1103091/7-incredible-reasons-to-buy-pfizer-stock-right-now
-
ALK afslutter første del af fase 1-studie med peanuttablet https://www.proinvestor.com/investornyt/1104844/alk-afslutter-forste-del-af-fase-1-studie-med-peanuttablet
-
ALK-Abelló: Europæisk registreringsansøgning for tabletvaccine accepteret til vurdering https://www.proinvestor.com/investornyt/1107851/alk-abello-europaeisk-registreringsansogning-for-tabletvaccine-accepteret-til-vurdering
-
Video...Genmab er i vælten, især efter afvisningen af voldgiftsagen. Men hvad er udsigterne for 2024? Zealand Pharma-aktien bliver ved med at stige - hvad driver stigningen, og er det holdbart? Novo Nordisk kommer med regnskab 31. januar - det har mange investorer store forventninger til. Et andet spændende regnskab er Bavarian Nordic. Hvad skal pengene i kassen bruges til? Det har Helge Larsen et bud på. Til sidst er der nyt fra Lundbeck og ALK-Abelló. https://www.proinvestor.com/boards/118263
-
$ 2,25 mia i Roundup sag. Bayer er forgiftet. https://www.reuters.com/legal/bayer-ordered-pay-225-billion-latest-roundup-trial-2024-01-26/
-
Hvad tænker I om Corbus Pharmaceuticals, steg 250% i fredags på baggrund af denne https://www.corbuspharma.com/press-releases/detail/402/crb-701-sys6002-a-next-generation-nectin-4-targeting
-
Lundbeck får positiv anbefaling af ekstra langtidsvirkende skizofrenimiddel https://www.proinvestor.com/investornyt/1109180/lundbeck-far-positiv-anbefaling-af-ekstra-langtidsvirkende-skizofrenimiddel
-
Pfizer fastholder guidance. https://s28.q4cdn.com/781576035/files/doc_financials/2023/q4/Q4-2023-PFE-Earnings-Release.pdf "Adjusted" EPS midtpunkt $ 2,15. Ved kurs 27,48 er forward PE 12,8. Sammenlign med Johnson&Johnson ca. 30.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind